MedTrace Logo

A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus

NCT03616912 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 830

Last updated 2023-01-30

Study results available
· View outcomes & findings →

Summary

The reason for this study is to see how effective and safe the study drug known as baricitinib is in participants with systemic lupus erythematosus (SLE).

Conditions

Interventions

DRUG

Baricitinib

Administered orally.

DRUG

Placebo

Administered orally.

Sponsors & Collaborators

Principal Investigators

  • Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) · Eli Lilly and Company

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-08-02
Primary Completion
2021-11-01
Completion
2022-03-09
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Austria
  • Belgium
  • Brazil
  • China
  • Croatia
  • Czechia
  • Germany
  • Greece
  • Hungary
  • Israel
  • Mexico
  • Netherlands
  • Russia
  • Switzerland
  • Taiwan
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03616912 on ClinicalTrials.gov